National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States, 2003
- PMID: 17218935
National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States, 2003
Abstract
Arthritis is the leading cause of disability in the United States, potentially limiting affected persons from walking a few blocks or climbing a flight of stairs. Using Medical Expenditure Panel Survey (MEPS) data, CDC analyzed national and state-specific direct costs (i.e., medical expenditures) and indirect costs (i.e., lost earnings) attributable to arthritis and other rheumatic conditions (AORC) in the United States during 2003. This report describes the results of that analysis, which indicated that, in 2003, the total cost of AORC in the United States was approximately 128 billion dollars (80.8 billion dollars in direct and 47.0 billion dollars in indirect costs), equivalent to 1.2% of the 2003 U.S. gross domestic product. Total costs attributable to AORC, by state/area, ranged from 225.5 million dollars in the District of Columbia to 12.1 billion dollars in California. Total costs attributable to AORC have increased substantially since 1997, and that increase is expected to continue because of the aging of the population and increases in obesity and physical inactivity. These findings signal the need for broader implementation of effective public health interventions, such as arthritis and chronic disease self-management programs, which can reduce medical expenditures among persons with AORC.
Similar articles
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
-
Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates.Arthritis Rheum. 2004 Jul;50(7):2317-26. doi: 10.1002/art.20298. Arthritis Rheum. 2004. PMID: 15248233
-
Update: direct and indirect costs of arthritis and other rheumatic conditions--United States, 1997.MMWR Morb Mortal Wkly Rep. 2004 May 14;53(18):388-9. MMWR Morb Mortal Wkly Rep. 2004. PMID: 15138399
-
Direct and indirect costs of arthritis and other rheumatic conditions--United States, 1997.MMWR Morb Mortal Wkly Rep. 2003 Nov 21;52(46):1124-7. MMWR Morb Mortal Wkly Rep. 2003. PMID: 14627951
-
The economic impact of the rheumatic diseases in the United States.J Rheumatol. 1989 Jul;16(7):867-84. J Rheumatol. 1989. PMID: 2527991 Review.
Cited by
-
Economic Evaluation of Glucosamine in Knee Osteoarthritis Treatments in Vietnam.Healthcare (Basel). 2023 Sep 8;11(18):2502. doi: 10.3390/healthcare11182502. Healthcare (Basel). 2023. PMID: 37761699 Free PMC article.
-
Perceived treatment satisfaction in patients with systemic rheumatic diseases treated with biologic therapies: results of a self-reported survey.Rheumatol Int. 2023 Jun;43(6):1151-1159. doi: 10.1007/s00296-023-05280-y. Epub 2023 Feb 14. Rheumatol Int. 2023. PMID: 36786872 Free PMC article.
-
Mechanical Unloading of Engineered Human Meniscus Models Under Simulated Microgravity: A Transcriptomic Study.Sci Data. 2022 Nov 30;9(1):736. doi: 10.1038/s41597-022-01837-x. Sci Data. 2022. PMID: 36450785 Free PMC article.
-
An economic evaluation of knee osteoarthritis treatments in Thailand.Front Pharmacol. 2022 Sep 26;13:926431. doi: 10.3389/fphar.2022.926431. eCollection 2022. Front Pharmacol. 2022. PMID: 36225578 Free PMC article.
-
Preliminary Evaluation of a New Orthotic for Patellofemoral and Multicompartment Knee Osteoarthritis.Rehabil Res Pract. 2021 Sep 6;2021:5923721. doi: 10.1155/2021/5923721. eCollection 2021. Rehabil Res Pract. 2021. PMID: 34540291 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical